IP Library Granted Patent US 9,629,831
Granted Patent B2
US 9,629,831 · App. 14/742,465 · Granted Apr 25, 2017

Benzamides and related inhibitors of factor XA

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,629,831
App. No.
14/742,465
Granted
Apr 25, 2017
Kind
B2
Abstract

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Claims (18)

1. A method for preventing or treating venous thrombosis in a human patient in need thereof comprising administering to said patient a tablet comprising a maleate salt of the following compound:

2. A method for preventing or treating venous thrombosis in a human patient in need thereof comprising administering to said patient a capsule comprising a maleate salt of the following compound:

3. A method for preventing or treating deep venous thrombosis in a human patient in need thereof comprising administering to said patient a tablet comprising a maleate salt of the following compound:

4. A method for preventing or treating deep venous thrombosis in a human patient in need thereof comprising administering to said patient a capsule comprising a maleate salt of the following compound:

5. A method for preventing or treating pulmonary embolism in a human patient in need thereof comprising administering to said patient a tablet comprising a maleate salt of the following compound:

6. A method for preventing or treating pulmonary embolism in a human patient in need thereof comprising administering to said patient a capsule comprising a maleate salt of the following compound:

7. The method of claim 1 , wherein the method comprises administering the tablet once daily.

8. The method of claim 2 , wherein the method comprises administering the capsule once daily.

9. The method of claim 1 , wherein the tablet further comprises microcrystalline cellulose and magnesium stearate.

10. The method of claim 2 , wherein the capsule further comprises microcrystalline cellulose and magnesium stearate.

11. The method of claim 3 , wherein the method comprises administering the tablet once daily.

12. The method of claim 5 , wherein the method comprises administering the tablet once daily.

13. The method of claim 4 , wherein the method comprises administering the capsule once daily.

14. The method of claim 6 , wherein the method comprises administering the capsule once daily.

15. The method of claim 3 , wherein the tablet further comprises microcrystalline cellulose and magnesium stearate.

16. The method of claim 5 , wherein the tablet further comprises microcrystalline cellulose and magnesium stearate.

17. The method of claim 4 , wherein the capsule further comprises microcrystalline cellulose and magnesium stearate.

18. The method of claim 6 , wherein the capsule further comprises microcrystalline cellulose and magnesium stearate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2015
From: ZHU, BING-YAN; ZHANG, PENGLIE; WANG, LINGYAN; HUANG, WENRONG; GOLDMAN, ERICK A.; LI, WENHAO; ZUCKETT, JINGMEI; SONG, YONGHONG; SCARBOROUGH, ROBERT M.
To: COR THERAPEUTICS, INC.
Reel/Frame 035955/0587 →
MERGER Recorded Jun 25, 2015
From: COR THERAPEUTICS, INC.
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 036028/0853 →